Reporting of Safety Events during Anti-VEGF Treatment: Pharmacovigilance in a Noninterventional Trial

Figure 3

Overall incidence rates of adverse events starting at each month of the study. Calculation of percentages was based on number of patients not discontinued in the respective month. Patients with multiple adverse events within one month were counted only once. An additional 77 events occurred after the 24-month study period. As the incidence rates are calculated based on the number of nondiscontinued patients, it was not possible to calculate the incidence rate for the AEs occurring after study end.